Physician profile
Tomas Martinez
NPI 1659937787
$2,491.68
in general payments reported to CMS, 2019-2025
15 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $255 · 2023: $374 · 2024: $743 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $540.53 | 2022-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $473.92 | 2023-2025 | Arexvy, Shingrix |
| Ucb, INC. | $179.65 | 2023-2024 | Fintepla, Briviact |
| Abbott Laboratories | $161.99 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $155.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $140.33 | 2024 | |
| Genzyme Corporation | $132.27 | 2023 | |
| Lilly USA, LLC | $122.79 | 2025 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $122.79 | 2024 | Zeposia |
| Emd Serono, INC. | $122.61 | 2025 | Mavenclad |
| Bayer Healthcare Pharmaceuticals INC. | $113.63 | 2025 | |
| Idorsia Pharmaceuticals US INC | $91.89 | 2022 | |
| Tg Therapeutics, INC. | $89.78 | 2024 | |
| Lundbeck LLC | $26.60 | 2022 | |
| Amgen INC. | $16.98 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.